| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YEXCR.2011.02.013 |
| P698 | PubMed publication ID | 21371474 |
| P2093 | author name string | Paul J Carter | |
| P2860 | cites work | Expression in Escherichia coli of chemically synthesized genes for human insulin | Q24599184 |
| Industrialization of mAb production technology: the bioprocessing industry at a crossroads | Q24655304 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Engineered therapeutic antibodies with improved effector functions | Q37524398 | ||
| Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology | Q37627408 | ||
| PEGylation of therapeutic proteins | Q37673091 | ||
| Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact | Q37686245 | ||
| Therapeutic antibodies for autoimmunity and inflammation | Q37736260 | ||
| Insulin and its analogs: actions via insulin and IGF receptors. | Q37781725 | ||
| Targeting antibodies to the cytoplasm | Q37811739 | ||
| Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier | Q37819809 | ||
| Advances in targeted therapeutic agents | Q38029122 | ||
| Increasing the serum persistence of an IgG fragment by random mutagenesis. | Q38344654 | ||
| Enhanced antibody half-life improves in vivo activity | Q40045495 | ||
| Assembly of a functional immunoglobulin Fv fragment in Escherichia coli | Q41278018 | ||
| High level Escherichia coli expression and production of a bivalent humanized antibody fragment | Q41642366 | ||
| Metrics for antibody therapeutics development | Q42556144 | ||
| Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. | Q44680126 | ||
| Designing CD4 immunoadhesins for AIDS therapy | Q46215386 | ||
| Escherichia coli secretion of an active chimeric antibody fragment. | Q54748397 | ||
| Ecallantide. | Q55052637 | ||
| Therapeutic antibody fragments with prolonged in vivo half-lives | Q56896528 | ||
| Quantitative Estimation of the Hybridization of Rabbit Antibodies | Q58996170 | ||
| Romiplostim | Q79763840 | ||
| Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon | Q82606411 | ||
| Biopharmaceutical benchmarks 2010 | Q85008502 | ||
| Catumaxomab: clinical development and future directions | Q28274519 | ||
| Tumor regression in cancer patients by very low doses of a T cell-engaging antibody | Q28290910 | ||
| Network medicine: a network-based approach to human disease | Q29547462 | ||
| The blood-brain barrier in health and chronic neurodegenerative disorders | Q29616411 | ||
| Engineered protein scaffolds as next-generation antibody therapeutics. | Q30377858 | ||
| Engineering novel binding proteins from nonimmunoglobulin domains | Q33224761 | ||
| Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs | Q33326938 | ||
| Thrombocytopenia caused by the development of antibodies to thrombopoietin | Q33339929 | ||
| Fully human antibodies from transgenic mouse and phage display platforms | Q33349660 | ||
| Display scaffolds: protein engineering for novel therapeutics | Q33350926 | ||
| Phage display derived therapeutic antibodies | Q33392248 | ||
| Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy | Q33586660 | ||
| Network systems biology for drug discovery | Q33592795 | ||
| Antibodies to watch in 2010 | Q33688243 | ||
| Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids | Q33698791 | ||
| A modeling analysis of the effects of molecular size and binding affinity on tumor targeting | Q33835328 | ||
| Monoclonal antibodies: versatile platforms for cancer immunotherapy | Q34111693 | ||
| Strategies and challenges for the next generation of therapeutic antibodies | Q34111699 | ||
| Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas | Q34147803 | ||
| Enhancement of therapeutic protein in vivo activities through glycoengineering | Q34180647 | ||
| Antibody-drug conjugates: targeted drug delivery for cancer | Q34621670 | ||
| Protein therapeutics: a summary and pharmacological classification | Q34728463 | ||
| From the bench to the bedside: ways to improve rituximab efficacy. | Q35822517 | ||
| Recombinant approaches to IgG-like bispecific antibodies | Q36139512 | ||
| Potent antibody therapeutics by design | Q36452621 | ||
| Human monoclonal antibodies from transgenic mice | Q37028982 | ||
| Fc-based cytokines : prospects for engineering superior therapeutics | Q37063591 | ||
| Antibody-drug conjugates for cancer therapy | Q37184293 | ||
| Molecular engineering and design of therapeutic antibodies | Q37227301 | ||
| The impact of PEGylation on biological therapies | Q37263179 | ||
| Monoclonal antibodies as innovative therapeutics | Q37347317 | ||
| Biosimilars--science, status, and strategic perspective | Q37415003 | ||
| Therapeutic antibodies: successes, limitations and hopes for the future | Q37491236 | ||
| Strategies to extend plasma half-lives of recombinant antibodies | Q37505008 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1261-1269 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Experimental Cell Research | Q1524289 |
| P1476 | title | Introduction to current and future protein therapeutics: a protein engineering perspective | |
| P478 | volume | 317 |
| Q89026861 | A "top-down" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery |
| Q47121163 | A Novel Affinity Tag, ABTAG, and Its Application to the Affinity Screening of Single-Domain Antibodies Selected by Phage Display |
| Q38305747 | A modular approach for assembling aldehyde-tagged proteins on DNA scaffolds |
| Q39917871 | A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens |
| Q36211427 | A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. |
| Q36385376 | A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator. |
| Q35762130 | A systematic study of glycopeptide esterification for the semi-quantitative determination of sialylation in antibodies |
| Q58869554 | ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds |
| Q27682484 | Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications |
| Q38287471 | Advanced Gene Manipulation Methods for Stem Cell Theranostics. |
| Q38846891 | Advances in PET Detection of the Antitumor T Cell Response |
| Q92594633 | Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability |
| Q46957910 | An immunohistochemical assay on human tissue using a human primary antibody |
| Q34632979 | Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages |
| Q90026464 | Antibody humanization-the Influence of the antibody framework on the CDR-H3 loop ensemble in solution |
| Q38058763 | Antigen generation and display in therapeutic antibody drug discovery -- a neglected but critical player |
| Q36328501 | Application of strain-promoted azide-alkyne cycloaddition and tetrazine ligation to targeted Fc-drug conjugates. |
| Q58603593 | Approaches to Resolve False Reporting in Neutralizing Antibody Assays Caused by Reagent Leaching from Affinity Capture Elution Solid Phase |
| Q92480844 | Batch-to-batch N-glycosylation study of infliximab, trastuzumab and bevacizumab, and stability study of bevacizumab |
| Q39346415 | Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations |
| Q38652655 | Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins |
| Q28066997 | Biopharmaceuticals from microorganisms: from production to purification |
| Q47980504 | CaF2 nanoparticles as surface carriers of GCAP1, a calcium sensor protein involved in retinal dystrophies. |
| Q51738953 | Cell growth stimulating effect of Ganoderma lucidum spores and their potential application for Chinese hamster ovary K1 cell cultivation. |
| Q58105699 | Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes |
| Q37612333 | Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. |
| Q38726992 | Cellular engineering for therapeutic protein production: product quality, host modification, and process improvement |
| Q26781607 | Challenges and opportunities for non-antibody scaffold drugs |
| Q36346851 | Challenges in design and characterization of ligand-targeted drug delivery systems |
| Q60919457 | Characterizing the Diversity of the CDR-H3 Loop Conformational Ensembles in Relationship to Antibody Binding Properties |
| Q50908651 | Chemical synthesis of biologically active monoglycosylated GM2-activator protein analogue using N-sulfanylethylanilide peptide. |
| Q50677188 | Chondrotinase ABC I thermal stability is enhanced by site-directed mutagenesis: a molecular dynamic simulations approach. |
| Q38364459 | Clinical pharmacology of bispecific antibody constructs. |
| Q61813729 | Comparative Analysis of Protein Quantification Methods for the Rapid Determination of Protein Loading in Liposomal Formulations |
| Q40724220 | Construction and immunogenicity of a new Fc-based subunit vaccine candidate against Mycobacterium tuberculosis. |
| Q38782837 | Controlled release and intracellular protein delivery from mesoporous silica nanoparticles |
| Q36781510 | Covalent Incorporation of Trehalose within Hydrogels for Enhanced Long-Term Functional Stability and Controlled Release of Biomacromolecules |
| Q38610135 | Data driven flexible backbone protein design |
| Q26821951 | Decoding mechanisms by which silent codon changes influence protein biogenesis and function |
| Q38137253 | Design and evaluation of radiolabeled tracers for tumor imaging |
| Q39591373 | Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing |
| Q38095360 | Developing therapeutic antibodies for neurodegenerative disease |
| Q90113232 | Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain |
| Q90312396 | Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer |
| Q34334475 | Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer |
| Q92669577 | Direct characterization of overproduced proteins by native mass spectrometry |
| Q35172930 | Discovery of binding proteins for a protein target using protein-protein docking-based virtual screening |
| Q28488034 | Dissection of agonistic and blocking effects of CD200 receptor antibodies |
| Q37284677 | Effects of protein transduction domain (PTD) selection and position for improved intracellular delivery of PTD-Hsp27 fusion protein formulations |
| Q91733844 | Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells |
| Q39005581 | Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. |
| Q57216451 | Encapsulation of albumin in self-assembled layer-by-layer microcapsules: comparison of co-precipitation and adsorption techniques |
| Q28071440 | Engineering Translation in Mammalian Cell Factories to Increase Protein Yield: The Unexpected Use of Long Non-Coding SINEUP RNAs |
| Q31032588 | Engineering bispecificity into a single albumin-binding domain |
| Q38220535 | Evaluation of genotoxicity testing of FDA approved large molecule therapeutics |
| Q41931233 | Expression of single-chain variable fragments fused with the Fc-region of rabbit IgG in Leishmania tarentolae |
| Q38743818 | FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality |
| Q38029985 | Fc-fusion proteins: new developments and future perspectives. |
| Q38799374 | Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. |
| Q62117794 | Functional protein nanostructures: a chemical toolbox |
| Q41917847 | High-level fed-batch fermentative expression of an engineered Staphylococcal protein A based ligand in E. coli: purification and characterization |
| Q44540221 | Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: observations from molecular dynamics simulations |
| Q27679445 | Improving biophysical properties of a bispecific antibody scaffold to aid developability |
| Q38675117 | Improving the targeting of therapeutics with single-domain antibodies. |
| Q38860463 | Inducing Stem Cell Myogenesis Using NanoScript. |
| Q38939816 | Interaction of CD154 with different receptors and its role in bidirectional signals. |
| Q51055585 | Intramolecular thioether crosslinking of therapeutic proteins to increase proteolytic stability. |
| Q38819455 | Investigational therapies for renal disease-induced anemia |
| Q36175045 | Kinetic Controlled Tag-Catcher Interactions for Directed Covalent Protein Assembly. |
| Q39692794 | LC-MS analysis combined with principal component analysis and soft independent modelling by class analogy for a better detection of changes in N-glycosylation profiles of therapeutic glycoproteins |
| Q30009438 | Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency |
| Q98771873 | Local and Global Rigidification Upon Antibody Affinity Maturation |
| Q39279201 | Metal ions guided self-assembly of therapeutic proteins for controllable release: from random to ordered aggregation |
| Q46556173 | Mining ancient proteins for next-generation drugs |
| Q51659532 | Molecular Insights into the Thermal Stability of mAbs with Variable-Temperature Ion-Mobility Mass Spectrometry. |
| Q37334700 | Molecular approaches for improved clotting factors for hemophilia |
| Q38017581 | Molecular engineering of antibodies for therapeutic and diagnostic purposes |
| Q26825548 | Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases |
| Q39067543 | Mutagenesis modulates the uptake efficiency, cell-selectivity, and functional enzyme delivery of a protein transduction domain |
| Q30587595 | NanoScript: a nanoparticle-based artificial transcription factor for effective gene regulation. |
| Q39151211 | Novel biotechnology approaches in colorectal cancer diagnosis and therapy |
| Q41851653 | On-the-resin N-terminal modification of long synthetic peptides |
| Q54270937 | Orchestrating the biosynthesis of an unnatural pyrrolysine amino Acid for its direct incorporation into proteins inside living cells. |
| Q89422301 | Overview of Antibody Drug Delivery |
| Q34951227 | PCSK9 prosegment chimera as novel inhibitors of LDLR degradation |
| Q38269324 | PEGylation and its impact on the design of new protein-based medicines. |
| Q42114642 | PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses |
| Q39093458 | Particle sizing methods for the detection of protein aggregates in biopharmaceuticals |
| Q55656986 | Peptide-Based Supramolecular Hydrogels for Delivery of Biologics. |
| Q50885364 | Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy. |
| Q48253463 | Progress in biopharmaceutical development. |
| Q38038410 | Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. |
| Q41603771 | Progressive Saturation Improves the Encapsulation of Functional Proteins in Nanoscale Polymer Vesicles |
| Q51624302 | Prolonged Release of Bioactive Model Proteins from Anionic Microgels Fabricated with a New Microemulsion Approach. |
| Q93381341 | Protein PEGylation for cancer therapy: bench to bedside |
| Q57345827 | Protein Therapeutic: Production, Application, and Future Scenario |
| Q38286271 | Protein engineering: a new frontier for biological therapeutics |
| Q38230560 | Protein folding and secretion: mechanistic insights advancing recombinant protein production in S. cerevisiae. |
| Q92672771 | Protein-Polymer Conjugates Synthesized Using Water-Soluble Azlactone-Functionalized Polymers Enable Receptor-Specific Cellular Uptake toward Targeted Drug Delivery |
| Q97636118 | Purification of protein therapeutics via high-affinity supramolecular host-guest interactions |
| Q38303016 | Quality assessment and optimization of purified protein samples: why and how? |
| Q38541950 | RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies |
| Q44287563 | Rapid development of multiple 'fit-for-purpose' assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs |
| Q39419740 | Rational design and evaluation of mammalian ribonuclease cytotoxins |
| Q35961236 | Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins |
| Q28485340 | Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes |
| Q29247996 | Recent Advances in Application of Pharmacogenomics for Biotherapeutics |
| Q38635135 | Recent advances and novel treatments for sphingolipidoses |
| Q39148639 | Recent advances in (therapeutic protein) drug development. |
| Q38265617 | Receptor-targeted drug delivery: current perspective and challenges. |
| Q38096411 | Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors |
| Q35005791 | Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody |
| Q42770604 | Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment. |
| Q41074700 | Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method |
| Q45969140 | Sequence and Solution Effects on the Prevalence of d-Isomers Produced by Deamidation. |
| Q58569258 | Silica-Based Nanoparticles for Protein Encapsulation and Delivery |
| Q26777819 | Site-Specific PEGylation of Therapeutic Proteins |
| Q35155487 | Site-specific Labeling of a Protein Lysine Residue By Novel Kinetic Labeling Combinatorial Libraries |
| Q92210823 | Site-specific N- and O-glycosylation analysis of atacicept |
| Q33894458 | Smart Release Nano-formulation of Cytochrome C and Hyaluronic Acid Induces Apoptosis in Cancer Cells |
| Q97547703 | Solid Phase Protein Modifications: Towards Precision Protein Hybrids for Biological Applications |
| Q38919744 | Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics |
| Q36530093 | Streamlined expressed protein ligation using split inteins. |
| Q44216882 | Structural and dynamic properties of monoclonal antibodies immobilized on CNTs: a computational study |
| Q58091462 | Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus |
| Q38764784 | Studies to Prevent Degradation of Recombinant Fc-Fusion Protein Expressed in Mammalian Cell Line and Protein Characterization |
| Q24601129 | Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag |
| Q51484265 | Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS. |
| Q92461831 | The Coming Age of Insect Cells for Manufacturing and Development of Protein Therapeutics |
| Q38092648 | The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics |
| Q35908498 | Therapeutic antibodies against cancer |
| Q26991608 | To fuse or not to fuse: what is your purpose? |
| Q61814870 | Toxin Neutralization Using Alternative Binding Proteins |
| Q38014920 | Using antibodies to target cancer therapeutics |
| Q35743857 | Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1. |
| Q61796365 | Web-based display of protein surface and pH-dependent properties for assessing the developability of biotherapeutics |
Search more.